Abeysekera, Kushala WM;
Srivastava, Ankur;
Rowe, Ian;
Jarvis, Helen;
Ryder, Stephen D;
Yeoman, Andrew;
Dillon, John F;
(2023)
Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys.
Frontline Gastroenterology
10.1136/flgastro-2023-102415.
(In press).
Preview |
Text (Accepted Manuscript)
Rosenberg_Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways_AAM.pdf Download (362kB) | Preview |
Preview |
Text (Supplementary Material)
Rosenberg_Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways_SuppM.pdf Download (1MB) | Preview |
Abstract
INTRODUCTION: The increasing availability of non-invasive tests (NITs) has created the opportunity to explore their use in improving risk stratification of advanced liver disease. The study aimed to determine the attitudes and practices among UK secondary care specialists, focusing primarily on attitudes to fibrosis assessment and the use of NITs. METHODS: Two web-based surveys were circulated, first between 2014 and 2015 (survey 1), and again in 2021 (survey 2). The surveys were promoted via the British Society of Gastroenterology, the British Association for the Study of the Liver and using Twitter. RESULTS: In survey 1, 215 healthcare professionals (HCPs) completed the online survey. 112 HCPs completed survey 2. 71 acute UK trusts were represented in survey 1 compared with 60 trusts in survey 2. Between the two surveys, the proportion of HCPs performing fibrosis assessment in all or nearly all cases rose from 45.1% to 74.1% (χ2=25.01; p<0.0001). 46.5% (n=33/71) respondents in acute services reported the use of NITs in clinical pathways in survey 1, rising to 70.0% (n=42/60) in survey 2 (χ2=7.35; p=0.007). Availability of tests has increased but is not universal. The proportion reporting availability as a barrier to uptake fell from 57.2% of responses in survey 1 to 38.4% in 2021 χ2=11.01; p=0.0009). CONCLUSION: Between 2014 and 2021, the role of NITs in fibrosis assessment has risen substantially, as has the proportion of clinicians using NITs in clinical pathways to assess risk of liver disease. Poor access to NITs remains the predominant barrier.
Archive Staff Only
 |
View Item |
